Efficacy of ukrain in the treatment of pancreatic cancer

Langenbecks Arch Surg. 2002 Jun;387(2):84-9. doi: 10.1007/s00423-002-0293-y. Epub 2002 Jun 19.


Background: This monocentric study evaluated the effect of ukrain in the treatment of pancreatic cancer.

Material and methods: Between January 1996 and December 1999 we treated 21 patients with 10 mg ukrain every second day x10. The control group received supportive treatment only.

Results: Ukrain treatment was well tolerated. Mean values on pain measure and Karnofsky index were significantly better in the ukrain group than in controls ( P<0.05). One-year survival was 76% in the ukrain group, compared to 9.5% in the control group. Median survival after treatment with ukrain was 574 days, compared to 197 days in the control group.

Conclusions: Our data demonstrate that ukrain improves quality of life in patients suffering from advanced pancreatic cancer and significantly prolongs survival time in these patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alkaloids / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Berberine Alkaloids
  • Female
  • Humans
  • Male
  • Middle Aged
  • Palliative Care
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / mortality
  • Phenanthridines
  • Pilot Projects
  • Prognosis
  • Quality of Life


  • Alkaloids
  • Antineoplastic Agents
  • Berberine Alkaloids
  • Phenanthridines
  • ukrain